Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/18/2025 07:14 PDT] DCTH Expected to Trade Up After Bullish Patterns Develop
• [06/10/2025 06:56 PDT] DCTH Expected to Trade Up After Bullish Patterns Develop
• [05/19/2025 14:55 PDT] Delcath Systems, Inc. (NASDAQ:DCTH), Up By 100% ($15.29) From $15.29 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/19/2025 12:43 PDT] Delcath Systems, Inc. (NASDAQ:DCTH), Up By 100% ($14.84) From $14.84 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/15/2025 06:53 PDT] DCTH Expected to Trade Up After Bullish Patterns Develop
• [05/12/2025 07:18 PDT] DCTH Expected to Trade Up After Bullish Patterns Develop
• [05/06/2025 07:20 PDT] DCTH Expected to Trade Down Short Term
• [05/01/2025 07:13 PDT] DCTH Expected to Trade Down Short Term